Merck & Co., Inc. (MRK) News
Latest headlines that mention MRK, newest first · each headline opens the original publisher
- Last price
- $142.38
- Day change
- -0.29%
- Next earnings
- 2026-10-29 BMO
MRK headlines
last 30 daysVaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck. The post Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study appeared first on Investor's Business Daily .
Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight? The post Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz appeared first on Investor's Business Daily .
Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech. The post AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck appeared first on Investor's Business Daily .
A private meeting with the drugmaker's top doctor points to the next make-or-break moment for shareholders.
Also mentioned with MRK
30dHeadlines that tag both tickers
MRK news alerts
Get an alert by email or push when a new headline mentions MRK.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.